NCT05814198 is a clinical trial of HALP score in Fetal Growth Restriction, sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization.

Who is sponsoring NCT05814198?

NCT05814198 is sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization.

What drugs are being tested in NCT05814198?

Interventions in NCT05814198: HALP score.

What condition does NCT05814198 study?

NCT05814198 studies Fetal Growth Restriction, Small for Gestational Age at Delivery.

Is NCT05814198 still recruiting?

NCT05814198 is currently completed. Last updated 29 August 2023.

Last reviewed 2023-08-29 · How we verify

NCT05814198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of HALP Score in Distinction Between FGR and SGA

Completed Last updated 29 August 2023

What this trial tests

trial testing HALP score in Fetal Growth Restriction in 400 participants. Completed in 15 June 2023.

Timeline

22 February 2023

Primary endpoint
22 May 2023

15 June 2023

Quick facts

Lead sponsor	Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Status	Completed
Study type	OBSERVATIONAL
Enrollment	400
Start date	22 February 2023
Primary completion	22 May 2023
Estimated completion	15 June 2023
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

HALP score

Conditions studied

Fetal Growth Restriction — all drugs for Fetal Growth Restriction →
Small for Gestational Age at Delivery — all drugs for Small for Gestational Age at Delivery →

Sponsor

Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

Who can join

Adults 18 to 44, female only, with Fetal Growth Restriction or Small for Gestational Age at Delivery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fetal Growth Restriction (FGR) and Small for Gestational Age (SGA) are two conditions that can happen when a baby doesn't grow as much as expected during pregnancy. FGR is caused by things like problems with the mother's nutrition and inflammation, while SGA is usually because of genetic and other factors. It's important to know if a baby has FGR or SGA because FGR babies can have more health problems and are at risk of dying before or shortly after birth. SGA babies are usually healthy, but they might have more health problems later in life. Doctors can use a simple blood test called the HALP score to see if a mother has problems with her nutrition and inflammation. However, it hasn't been studied for FGR and SGA. We want to study if the HALP score can help us tell if a baby has FGR or SGA by looking at the mother's blood test results.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Fetal Growth Restriction

Currently open trials in the same condition.

NCT06919692 — Maternal Left Lateral Position in Fetal Growth Restriction · NA · recruiting
NCT07015203 — The Combined First Trimester Screening · recruiting
NCT06497959 — Study of Placental Vascularization Using Contrast Ultrasound · Phase 3 · recruiting
NCT05674487 — Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN) · NA · recruiting
NCT06372938 — Role of Inflammatory Markers and Doppler Parameters in Late-Onset Fetal Growth Restriction: A Machine Learning Approach · active not recruiting

Other Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization trials

Trials by the same sponsor.

NCT07500285 — Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Ph · Phase 2 · not yet recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07390279 — Efficacy of Transcutaneous Pulsed Radiofrequency in Postherpetic Neuralgia · recruiting
NCT07357922 — Serum Progesterone and Threatened Abortion During Lactation · not yet recruiting
NCT07283250 — Development and Validation of the Air Quality Awareness Scale (AQAS) for Parents · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05814198 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Last refreshed: 29 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05814198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing